{"id":6811,"date":"2026-03-18T18:02:13","date_gmt":"2026-03-18T18:02:13","guid":{"rendered":"https:\/\/www.europesays.com\/news\/6811\/"},"modified":"2026-03-18T18:02:13","modified_gmt":"2026-03-18T18:02:13","slug":"jj-wins-approval-for-first-of-its-kind-psoriasis-pill","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/news\/6811\/","title":{"rendered":"J&J wins approval for first-of-its-kind psoriasis pill"},"content":{"rendered":"

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT\u2019s industry-leading events.<\/p>\n

Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could roil a multibillion-dollar market.<\/p>\n

The drug, Icotyde, is approved for patients over the age of 12 with moderate to severe plaque psoriasis, J&J said Wednesday. Developed as icotrokinra, Icotyde is designed to mimic the effects of top-selling psoriasis treatments, including AbbVie\u2019s Skyrizi and J&J\u2019s own Tremfya, without the need for needles.<\/p>\n

\t\t\t\"\"\t\t<\/p>\n

\t\t\t\t\"\"\/
\n\t\t\t\tSTAT Plus: Health tech company says it will dive into Medicare\u2019s new chronic care experiment<\/a><\/p>\n

Analysts expect J&J\u2019s drug to reshape one of the most competitive fields in the pharmaceutical industry. Patients with psoriasis typically cycle through topical drugs before getting prescribed an injectable therapy, and many opt out of treatment for reasons of convenience or cost. Icotyde has the potential to expand the market, according to J&J, and the company expects the drug to bring in more than $5 billion in annual sales at its peak.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing…\n","protected":false},"author":2,"featured_media":6812,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1433,2861,8,9,1435,2400,7],"class_list":{"0":"post-6811","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-top-stories","8":"tag-biotechnology","9":"tag-chronic-disease","10":"tag-headlines","11":"tag-news","12":"tag-pharmaceuticals","13":"tag-stat","14":"tag-top-stories"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@news\/116251495184615219","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/posts\/6811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/comments?post=6811"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/posts\/6811\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/media\/6812"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/media?parent=6811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/categories?post=6811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/news\/wp-json\/wp\/v2\/tags?post=6811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}